摘要
目的探讨二甲双胍对合并2型糖尿病的肝癌患者射频/微波消融术后无复发生存期及总生存期的影响。方法选择2014年1月至2019年9月收治的合并2型糖尿病的原发性肝癌患者70例,患者均进行肝癌射频/微波消融术治疗,按是否口服二甲双胍将患者分为2组;二甲双胍单独或联合其他降血糖药物组为观察组(n=34),且二甲双胍在射频消融术后连续口服≥6个月;不包含二甲双胍降糖药物组为对照组(n=36)。Kaplan-Meier法、Cox比例风险模型计算协变量风险比(HR)和95%置信区间(CIs)进行分析。结果肝癌射频/微波消融术后使用二甲双胍的肝癌患者有较低的复发率(HR=0.522,95%CI:0.28~0.97),并与肿瘤特征相关,是无复发生存期的一个危险因素。二甲双胍可延长总生存期。结论二甲双胍对肝癌有抑制作用,二甲双胍可以降低合并2型糖尿病的肝癌术后复发率,提高肝癌患者总生存率,改善患者的预后。
Objective To study the effect of metformin on the relapse-free survival and the overall survival of liver cancer patients combined with type 2 diabetes mellitus(T2DM)after radiofrequency/microwave ablation.Methods A total of 70 primary liver cancer patients combined with T2DM who were admitted from January 2014 to September 2019 were selected.All patients were treated with radiofrequency/microwave ablation for liver cancer.Patients were divided into two groups according to the oral medication of metformin or not.Patients with a monotherapy of oral metformin for a minimum of consecutive 6 months after microwave ablation or its combination treatment with other hypoglycemic drugs were included in the observation group(n=34),while those who did not medicated with metformin were included in the control group(n=36).Kaplan-Meier method and Cox proportional risk model were used to calculate the hazard ratio(HR)and the corresponding 95%confidence interval(CI).Results Liver cancer patients combined with T2DM who were orally medicated with metformin after radiofrequency/microwave ablation had a significantly lower recurrent rate(HR=0.522,95%CI:0.28-0.97),which was correlated with the tumor characteristic as a risk factor for the recurrence-free survival.Metformin contributed to prolong the overall survival of liver cancer patients combined with T2DM.Conclusion For liver cancer patients combined with T2DM,metformin can inhibit liver cancer,reduce postoperative recurrence rate,increase overall survival rate and improve prognosis.
作者
卢伟娜
李冀宏
王建民
董金红
李邵凝
刘文宗
贾志强
王德华
LU Weina;LI Jihong;WANG Jianmin(Department of Hepatology,Shijiazhuang Fifth Hospital,Hebei,Shijiazhuang 050017,China)
出处
《河北医药》
CAS
2023年第17期2636-2639,共4页
Hebei Medical Journal
基金
河北省医学科学研究重点课题计划(编号:20181078)。
关键词
二甲双胍
原发性肝癌
射频/微波消融术
2型糖尿病
metformin
primary liver cancer
radiofrequency/microwave ablation
type 2 diabetes mellitus
